Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 6/20 | 0.63 |
| ▸ | CA2 | P00918 | 2/20 | 0.63 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL107126 | 0.78 | CA9 (1.00) | CA9CA2HSD11B1CYP2C19CA12 | |
| SCHEMBL30339085 | 0.78 | CA9 (1.00) | CA9CA2HSD11B1CYP2C19CA12 | |
| SCHEMBL14294228 | 0.76 | CYP2C9 (0.64) | CA9CA2HSD11B1CYP1A2CYP2C9 | |
| SCHEMBL22214051 | 0.76 | CA9 (0.44) | CA9CA2CA12ELANEMAPT | |
| SCHEMBL13402635 | 0.74 | CA9 (0.61) | CA9CA2HSD11B1CYP1A2CYP2C9 | |
| SCHEMBL12606536 | 0.74 | KDM4E (0.52) | CA9CA2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18537353 | 0.74 | CA9 (0.61) | CA9CA2HSD11B1CYP1A2CYP2C9 | |
| SCHEMBL10021585 | 0.72 | HSD11B1 (0.58) | CA9CA2HSD11B1CYP1A2CYP2C9 | |
| SCHEMBL19194634 | 0.72 | CA9 (0.62) | CA9CA2HSD11B1CYP1A2CYP2C9 | |
| SCHEMBL13069407 | 0.69 | CA9 (0.54) | CA9CA2HSD11B1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093397-B2 | Activators for oligonucleotide synthesis | AVECIA BIOTECHNOLOGY, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090085006-A1 | Activators for oligonucleotide synthesis | AVECIA BIOTECHNOLOGY, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-7476709-B2 | Process for preparing oligonucleotides | AVECIA BIOTECHNOLOGY INC. (US) | 2009-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090085006-A1 | Activators for oligonucleotide synthesis | MED12, ORC3, NOP2 | CA9 4498/4885CA2 3480/4885HSD11B1 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.